6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Originaltext

Diese Übersetzung bewerten

Mit deinem Feedback können wir Google Übersetzer weiter verbessern

Latest Press Releases

Time	Headline
18m ago	Hexaware Reports Q1CY26 Revenue at USD 388.5 Mn, Up 4.6% YoY Q1CY26 EPS at INR 5.77, Increase of 7.2% YoY
19m ago	Digitalage Enters Production Validation: Creator Cohort Activation Begins as Submitted Apps Move Through Platform Review
50m ago	Pagaya Issues AAA-rated Upsized $800 Million Personal Loan ABS Transaction
51m ago	American Water Recognized on Forbes 2026 List of America's Best Employers for Company Culture
51m ago	PERMIAN BASIN ROYALTY TRUST ANNOUNCES CHANGE IN TIME OF HEARING ON MAY 8, 2026

About

Neurizon Therapeutics Limited — investor relations, events, news, and company updates on 6ix.

Latest News

Placement of Entitlement Offer Shortfall

NUZ-001 Data Shows Multi-Pathway Protein Clearance

Neurizon announces leadership transition

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Neurizon Initiates Dosing in HEALEY ALS Platform Trial

How Neurizon Therapeutics Limited runs its investor program on 6ix — audience, formats, and program overview.

Recent Videos

Neurizon Therapeutics' NUZ-001 is building momentum in ALS trial

Neurizon Therapeutics' NUZ-001 is building momentum in ALS trial

Apr 07, 2026

HEALEY ALS Platform Trial Webinar: March 19, 2026 | Regimen I (NUZ-001) Science

HEALEY ALS Platform Trial Webinar: March 19, 2026 | Regimen I (NUZ-001) Science

Mar 31, 2026

Neurizon Therapeutics doses first patient in HEALY ALS platform trial

Neurizon Therapeutics doses first patient in HEALY ALS platform trial

Feb 27, 2026

Neurizon: Potentially developing a treatment for motor neurone disease

Neurizon: Potentially developing a treatment for motor neurone disease

Feb 26, 2026

Community Chat

Ask AI